-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 5, foreign media reported that the new crown vaccine jointly developed by AstraZeneca and Oxford University has been approved in Germany for people over 65 years of age.
The Vaccination Committee of the German Ministry of Health recommends that the interval between the first and second doses of the AstraZeneca/Oxford vaccine be extended up to 12 weeks.
Earlier this year, the German "Business Daily" and "Bild" respectively reported that the AstraZeneca/Oxford vaccine is only 8% or less than 10% effective for people 65 years of age and older.
Both the European Medicines Agency (EMA) and the World Health Organization (WHO) recommend the use of AstraZeneca/Oxford vaccines for people over 65 years of age.
A recent real-world study by the Department of Public Health of the United Kingdom (PHE) also found that the AstraZeneca/Oxford vaccine can significantly reduce the incidence of severe new crowns in the elderly.
German Health Minister Jens Spahn announced the committee’s decision last Thursday.